Geron Corp
Open
SectorHealthcare
1.37 -4.2
Overview
Share price change
24h
Min
1.3599999999999999
Max
1.43
Income | -13M -17M |
|---|---|
Sales | 5.6M 57M |
EPS | -0.02 |
Profit margin | -29.019 |
Employees | 258 |
EBITDA | -16M -12M |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 188M 1B |
|---|---|
Previous open | 5.57 |
Previous close | 1.37 |
News Sentiment
By Acuity
38%
62%
106 / 339 Healthcare
Geron Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Sentiment
By Acuity
106 / 339 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.